東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Pharmaceutical research and developm...

King, Timothy D. N.

FindBook

Google Book

Amazon

博客來

Pharmaceutical research and development: A key informant assessment of whether an "open-science" model could improve clinical research in terms of quality and efficiency.

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Pharmaceutical research and development: A key informant assessment of whether an "open-science" model could improve clinical research in terms of quality and efficiency./
作者:	King, Timothy D. N.
面頁冊數:	146 p.
附註:	Source: Dissertation Abstracts International, Volume: 75-01(E), Section: B.
Contained By:	Dissertation Abstracts International75-01B(E).
標題:	Health Sciences, Pharmacy. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3594114
ISBN:	9781303377488

Pharmaceutical research and development: A key informant assessment of whether an "open-science" model could improve clinical research in terms of quality and efficiency.
King, Timothy D. N.

Pharmaceutical research and development: A key informant assessment of whether an "open-science" model could improve clinical research in terms of quality and efficiency. - 146 p.

Source: Dissertation Abstracts International, Volume: 75-01(E), Section: B.

Thesis (Dr.P.H.)--The University of North Carolina at Chapel Hill, 2013.

The average cost to develop each new pharmaceutical drug is approximately $1 billion or more and takes 12-15 years from laboratory concept to an approved drug on the shelf at the local pharmacy. There is concern that the high cost and extended timelines required for pharmaceutical research and development (R&D;) is not sustainable in the long term, as pharmaceutical companies question the value of investing $1 billion against an uncertain future revenue stream. The high cost of R&D; contributes to the high cost of pharmacotherapies to consumers, where one recent estimate projects that annual global spending on pharmaceuticals will exceed $1.2 trillion by 2016.

ISBN: 9781303377488Subjects--Topical Terms:

1017737
Health Sciences, Pharmacy.

Pharmaceutical research and development: A key informant assessment of whether an "open-science" model could improve clinical research in terms of quality and efficiency.
LDR:03394nam a2200325 4500 001 1961644
005 20140714103013.5
008 150210s2013 ||||||||||||||||| ||eng d
020 $a 9781303377488
035 $a (MiAaPQ)AAI3594114
035 $a AAI3594114
040 $a MiAaPQ $c MiAaPQ
100 1 $a King, Timothy D. N. $3 2097582
245 1 0 $a Pharmaceutical research and development: A key informant assessment of whether an "open-science" model could improve clinical research in terms of quality and efficiency.
300 $a 146 p.
500 $a Source: Dissertation Abstracts International, Volume: 75-01(E), Section: B.
500 $a Adviser: John E. Paul.
502 $a Thesis (Dr.P.H.)--The University of North Carolina at Chapel Hill, 2013.
520 $a The average cost to develop each new pharmaceutical drug is approximately $1 billion or more and takes 12-15 years from laboratory concept to an approved drug on the shelf at the local pharmacy. There is concern that the high cost and extended timelines required for pharmaceutical research and development (R&D;) is not sustainable in the long term, as pharmaceutical companies question the value of investing $1 billion against an uncertain future revenue stream. The high cost of R&D; contributes to the high cost of pharmacotherapies to consumers, where one recent estimate projects that annual global spending on pharmaceuticals will exceed $1.2 trillion by 2016.
520 $a Spending over $1 trillion on pharmaceuticals each year is a burden on global health resources. Therefore, reducing the cost of pharmaceuticals could have a tremendous impact on patients' access to healthcare. A potential source of cost reduction is to improve efficiency in pharmaceutical R&D; while protecting patient safety and maintaining or improving research quality. If savings in pharmaceutical R&D; could be passed on to consumers, this would result in lower pharmaceutical prices and healthcare costs worldwide.
520 $a One concept proposed to improve R&D; efficiency and quality is to make the process more transparent and collaborative where researchers, even those from competing pharmaceutical companies, could more freely share information on their research designs, processes and outcomes. This concept, "open-science" R&D; (OSRD), differs from traditional R&D; approaches that typically are more secretive and less collaborative.
520 $a To explore whether OSRD could be a viable and beneficial alternative to current pharmaceutical R&D; practices, key informants from academia, industry, and regulatory agencies were interviewed using a qualitative, semi-structured questionnaire. While the key informants were concerned that for-profit pharmaceutical companies would not voluntarily embrace OSRD, the results also revealed that, 1) OSRD may be more efficient and therefore better in terms of R&D; costs, 2) many OSRD-type activities are already in place, 3) more transparency is probably inevitable, and 4) senior leaders, including those in industry, are open to exploring opportunities for broad transparency and collaboration such as those envisioned in OSRD.
590 $a School code: 0153.
650 4 $a Health Sciences, Pharmacy. $3 1017737
650 4 $a Health Sciences, Medicine and Surgery. $3 1017756
650 4 $a Health Sciences, Public Health. $3 1017659
690 $a 0572
690 $a 0564
690 $a 0573
710 2 $a The University of North Carolina at Chapel Hill. $b Health Policy And Management. $3 1020346
773 0 $t Dissertation Abstracts International $g 75-01B(E).
790 $a 0153
791 $a Dr.P.H.
792 $a 2013
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3594114